While NewAmsterdam Pharma Company NV has overperformed by 0.49%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NAMS fell by -4.90%, with highs and lows ranging from $27.29 to $14.06, whereas the simple moving average jumped by 15.34% in the last 200 days.
On July 17, 2025, Goldman started tracking NewAmsterdam Pharma Company NV (NASDAQ: NAMS) recommending Neutral. A report published by Citigroup on June 17, 2025, Initiated its previous ‘Buy’ rating for NAMS. Stifel also rated NAMS shares as ‘Buy’, setting a target price of $44 on the company’s shares in an initiating report dated June 10, 2025. Cantor Fitzgerald Initiated an Overweight rating on June 04, 2025, and assigned a price target of $42. H.C. Wainwright initiated its ‘Buy’ rating for NAMS, as published in its report on December 30, 2024. Scotiabank also rated the stock as ‘Sector Outperform’.
Analysis of NewAmsterdam Pharma Company NV (NAMS)
Further, the quarter-over-quarter increase in sales is 740.06%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of NewAmsterdam Pharma Company NV’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -28.43% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 21.08, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and NAMS is recording an average volume of 865.12K. On a monthly basis, the volatility of the stock is set at 5.39%, whereas on a weekly basis, it is put at 4.15%, with a loss of -2.90% over the past seven days. Furthermore, long-term investors anticipate a median target price of $41.00, showing growth from the present price of $24.44, which can serve as yet another indication of whether NAMS is worth investing in or should be passed over.
How Do You Analyze NewAmsterdam Pharma Company NV Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 44.54%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 61.57% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
